Supernus Pharmaceuticals Stock Options
| SUPN Stock | USD 38.69 0.31 0.79% |
Supernus Pharmaceuticals' latest option contracts expiring on March 21st 2025 are carrying combined implied volatility of 0.8 with a put-to-call open interest ratio of 0.34 over 36 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on March 21st 2025.
Open Interest Against March 21st 2025 Option Contracts
2025-03-21
The chart above shows Supernus Pharmaceuticals' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Supernus Pharmaceuticals' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Supernus Pharmaceuticals' option, there is no secondary market available for investors to trade.
Supernus Pharmaceuticals Maximum Pain Price Across 2025-03-21 Option Contracts
Max pain occurs when Supernus Pharmaceuticals' market makers reach a net positive position across all Supernus Pharmaceuticals' options at a strike price where option holders stand to lose the most money. By contrast, Supernus Pharmaceuticals' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Supernus Pharmaceuticals
Analyzing Supernus Pharmaceuticals' in-the-money options over time can help investors to take a profitable long position in Supernus Pharmaceuticals regardless of its overall volatility. This is especially true when Supernus Pharmaceuticals' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Supernus Pharmaceuticals' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Supernus Pharmaceuticals' stock while costing only a fraction of its price.
Please note that buying 'in-the-money' options on Supernus Pharmaceuticals lessens the impact of time decay, as they carry both intrinsic and time value. So, even if Supernus Pharmaceuticals' value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money Supernus Pharmaceuticals contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if Supernus Stock moves the wrong way.
Supernus Pharmaceuticals In The Money Call Balance
When Supernus Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Supernus Pharmaceuticals stock is said to be in the money. When it comes to buying Supernus Pharmaceuticals' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Supernus Pharmaceuticals are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Supernus Current Options Market Mood
Supernus Pharmaceuticals' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Supernus Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Supernus Pharmaceuticals' options investors are not very successful. Supernus Pharmaceuticals' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Supernus contract
Base on the Rule 16, the options market is currently suggesting that Supernus Pharmaceuticals will have an average daily up or down price movement of about 0.05% per day over the life of the 2025-03-21 option contract. With Supernus Pharmaceuticals trading at USD 38.69, that is roughly USD 0.0193. If you think that the market is fully incorporating Supernus Pharmaceuticals' daily price movement you should consider buying Supernus Pharmaceuticals options at the current volatility level of 0.8%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Supernus |
Purchasing Supernus Pharmaceuticals options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Supernus calls. Remember, the seller must deliver Supernus Pharmaceuticals stock to the call owner when a call is exercised.
Supernus Pharmaceuticals Option Chain
When Supernus Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Supernus Pharmaceuticals stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Supernus Pharmaceuticals' option chain is a display of a range of information that helps investors for ways to trade options on Supernus. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Supernus. It also shows strike prices and maturity days for a Supernus Pharmaceuticals against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | SUPN250321C00020000 | 3 | 20.0 | 17.6 - 21.5 | 16.9 | In |
Call | SUPN250321C00022000 | 104 | 22.0 | 15.8 - 19.5 | 15.86 | In |
Call | SUPN250321C00030000 | 55 | 30.0 | 8.5 - 12.0 | 8.2 | In |
Call | SUPN250321C00032000 | 7 | 32.0 | 6.5 - 10.5 | 6.4 | In |
Call | SUPN250321C00033000 | 5 | 33.0 | 5.4 - 7.6 | 3.0 | In |
Call | SUPN250321C00034000 | 9 | 34.0 | 5.4 - 7.1 | 4.5 | In |
Call | SUPN250321C00035000 | 8 | 35.0 | 4.0 - 7.0 | 5.69 | In |
Call | SUPN250321C00036000 | 46 | 36.0 | 3.5 - 6.5 | 4.6 | In |
Call | SUPN250321C00037000 | 4 | 37.0 | 3.0 - 7.0 | 3.2 | In |
Call | SUPN250321C00038000 | 3 | 38.0 | 2.55 - 6.3 | 3.2 | In |
Call | SUPN250321C00039000 | 2 | 39.0 | 1.7 - 6.0 | 3.8 | Out |
Call | SUPN250321C00040000 | 110 | 40.0 | 1.7 - 4.9 | 3.7 | Out |
Call | SUPN250321C00045000 | 15 | 45.0 | 0.0 - 1.95 | 1.5 | Out |
Call | SUPN250321C00050000 | 0 | 50.0 | 0.0 - 3.0 | 3.0 | |
Call | SUPN250321C00055000 | 1 | 55.0 | 0.0 - 0.85 | 0.85 | Out |
Put | SUPN250321P00021000 | 2 | 21.0 | 0.0 - 4.8 | 0.8 | Out |
Put | SUPN250321P00022000 | 3 | 22.0 | 0.0 - 0.95 | 0.85 | Out |
Put | SUPN250321P00023000 | 2 | 23.0 | 0.0 - 0.95 | 0.7 | Out |
Put | SUPN250321P00024000 | 1 | 24.0 | 0.0 - 0.95 | 1.85 | Out |
Put | SUPN250321P00025000 | 2 | 25.0 | 0.0 - 0.95 | 1.05 | Out |
Put | SUPN250321P00026000 | 2 | 26.0 | 0.0 - 0.5 | 1.2 | Out |
Put | SUPN250321P00028000 | 9 | 28.0 | 0.0 - 1.55 | 1.2 | Out |
Put | SUPN250321P00029000 | 2 | 29.0 | 0.0 - 1.75 | 1.24 | Out |
Put | SUPN250321P00030000 | 11 | 30.0 | 0.0 - 3.9 | 1.09 | Out |
Put | SUPN250321P00031000 | 2 | 31.0 | 0.0 - 2.05 | 1.45 | Out |
Put | SUPN250321P00033000 | 4 | 33.0 | 0.25 - 2.55 | 2.0 | Out |
Put | SUPN250321P00034000 | 10 | 34.0 | 0.3 - 2.75 | 2.69 | Out |
Put | SUPN250321P00035000 | 18 | 35.0 | 0.0 - 3.2 | 2.64 | Out |
Put | SUPN250321P00036000 | 59 | 36.0 | 0.0 - 3.6 | 3.0 | Out |
Put | SUPN250321P00037000 | 0 | 37.0 | 0.55 - 4.4 | 0.55 | |
Put | SUPN250321P00038000 | 0 | 38.0 | 1.95 - 4.9 | 1.95 | |
Put | SUPN250321P00039000 | 0 | 39.0 | 2.65 - 5.7 | 2.65 | In |
Put | SUPN250321P00040000 | 0 | 40.0 | 3.2 - 4.6 | 3.2 | In |
Put | SUPN250321P00045000 | 0 | 45.0 | 6.1 - 8.7 | 6.1 | In |
Put | SUPN250321P00050000 | 0 | 50.0 | 10.0 - 13.0 | 10.0 | In |
Put | SUPN250321P00055000 | 0 | 55.0 | 14.1 - 17.6 | 14.1 | In |
Supernus Pharmaceuticals Selling And Marketing Expenses Over Time
Selling And Marketing Expenses |
| Timeline |
Supernus Pharmaceuticals Market Cap Over Time
Market Cap |
| Timeline |
Supernus Total Stockholder Equity
Total Stockholder Equity |
|
Supernus Pharmaceuticals Corporate Management
| Padmanabh Bhatt | Chief Scientific Officer and Sr. VP of Intellectual Property | Profile | |
| Tami Martin | VP Affairs | Profile | |
| Jeff Bozick | Senior Chain | Profile | |
| Kevin Esq | Compliance Officer | Profile | |
| Taylor Raiford | Senior Sales | Profile | |
| Bryan Roecklein | Senior Development | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share | Quarterly Revenue Growth 0.142 | Return On Assets |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.